AstraZeneca PLC (AZNCF)

Market Cap	282.32B
Revenue (ttm)	58.13B
Net Income (ttm)	9.40B
Shares Out	n/a
EPS (ttm)	6.02
PE Ratio	30.04
Forward PE	18.12
Dividend	3.13 (1.71%)
Ex-Dividend Date	Aug 7, 2025

Volume	4,909
Average Volume	1,969
Open	172.68
Previous Close	191.13
Day's Range	172.68 - 183.20
52-Week Range	122.26 - 192.90
Beta	0.19
RSI	48.61
Earnings Date	Feb 10, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 94,300
• Stock Exchange: OTCMKTS
• Ticker Symbol: AZNCF

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.